Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03447730 · ClinicalTrials.gov registry record · Phase 1
Safety, Tolerability and Pharmacodynamics of SYNB1020
A Phase 1 study, sponsored by Synlogic.
- Terminated
- Registry status
- Phase 1
- Development phase
- 23
- Enrollment target
NCT03447730 is a Phase 1 study that was terminated before completion, run by Synlogic. The registered enrollment target is 23 participants.
The verdict
NCT03447730, a Phase 1 study, was terminated before completion, sponsored by Synlogic.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 23 participants
- Enrollment target
Study Summary
This Phase 1b/2a, randomized, double-blind, placebo-controlled study was designed to evaluate the safety, tolerability, and pharmacodynamics of SYNB1020 in hepatic insufficiency and cirrhosis patients with hyperammonemia, with dosing of the investigational medicinal product (IMP) administered in an inpatient unit and subsequent outpatient follow-up for SYNB1020 clearance in two study parts.
Interventions
- OTHER Placebo
- DRUG SYNB1020
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2018-03-19 |
| Est. Completion | 2019-07-19 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03447730
The ClinicalTrials.gov registry entry for NCT03447730 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 23 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Synlogic, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03447730 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03447730 about?
NCT03447730 is a clinical study titled "Safety, Tolerability and Pharmacodynamics of SYNB1020". This Phase 1b/2a, randomized, double-blind, placebo-controlled study was designed to evaluate the safety, tolerability, and pharmacodynamics of SYNB1020 in hepatic insufficiency and cirrhosis patients with hyperammonemia, with dosing of the investigational medicinal product (IMP) administered in an ...
What is the current status of trial NCT03447730?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 23 participants. The study started on 2018-03-19. Estimated completion is 2019-07-19.
What interventions are being tested in trial NCT03447730?
The interventions under investigation include: Placebo (OTHER), SYNB1020 (DRUG).
Who is sponsoring clinical trial NCT03447730?
This trial is sponsored by Synlogic, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.